In the unadjusted model (model 1), compared with individuals in baseline serum APOA1 levels in group 1, the odds ratios (ORs) and 95% confidence intervals (CI) for NAFLD prevalence were 0.814 (0.731-.905), 0.568 (0.508-0.636), and 0.382 (0.339-0.431) for individuals in group 2, group 3, and group 4, respectively. Here, APOA1 is linked to metabolic dysfunction-associated steatotic liver disease.